leisure time -WSS

leisure time

author：entertainment 2025-09-27 12:35:16 - browse：6

Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Hollywood unions extend contract negotiations for actors
Next article： The creative science of coining drug names

WSS

At ASCO, AstraZeneca reports strong data for breast cancer drug

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Deliver public health messages at the right time

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Sepsis can kill a child within hours. Here's how hospitals are fighting back

focus

leisure time

hotspot

Bright Health sells Medicare Advantage business to Molina

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

ASCO: AstraZeneca says CAR

Hepatitis C has a cure — but many Americans still lack access to it

Crowdfunding for medical bills sidesteps core problem, author says

Heart attack and stroke risk calculators need revising

FDA's Pazdur wants cancer trials to range beyond China alone

Medicare details structure of new drug price negotiation program

NIH documents show early flaws of $1.6 billion long Covid program

leisure time

GSK’s asthma push continues as drug succeeds in Phase 3 trials

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

With trial win, GSK could get blood cancer drug back on market

Ionis drug prevents swelling attacks due to hereditary angioedema

The effects of a landmark ruling on DNA ownership are becoming clearer

AltruBio raises $225 million to develop ulcerative colitis drug

explore

hotspot

hotspot

focus